Rosiglitazone Inhibits Transforming Growth Factor-β1 Mediated Fibrogenesis in ADPKD Cyst-Lining Epithelial Cells
Authors:
Open Access
- 9 December 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (12) , e28915
Abstract
Interstitial fibrosis plays an important role in progressive renal dysfunction in autosomal dominant polycystic kidney disease (ADPKD). In our previous studies, we confirmed that PPAR-γ agonist, rosiglitazone could protect renal function and prolong the survival of a slowly progressive ADPKD animal model by reducing renal fibrosis. However, the mechanism remains unknown. Primary culture epithelial cells pretreated with TGF-β1 were incubated with rosiglitazone. Extracellular matrix proteins were detected using real-time PCR and Western blotting. MAPK and Smad2 phosphorylation were measured with western blot. ERK1/2 pathway and P38 pathway were inhibited with the specific inhibitors PD98059 and SB203580. The Smad2 pathway was blocked with the siRNA. To address whether PPAR-γ agonist-mediated inhibition of TGF-β1–induced collagen type I expression was mediated through a PPAR-γ dependent mechanism, genetic and pharmaceutical approaches were used to block the activity of endogenous PPARγ. TGF-β1-stimulated collagen type I and fibronectin expression of ADPKD cyst-lining epithelia were inhibited by rosiglitazone in a dosage-dependent manner. Smad2, ERK1/2 and P38 pathways were activated in response to TGF-β1; however, TGF-β1 had little effect on JNK pathway. Rosiglitazone suppressed TGF-β1 induced Smad2 activation, while ERK1/2 and P38MAPK signals remained unaffected. Rosiglitazone could also attenuate TGF-β1-stimulated collagen type I and fibronectin expression in primary renal tubular epithelial cells, but had no effect on TGF-β1–induced activation of Smad2, ERK1/2 and P38 pathways. There was no crosstalk between the Smad2 and MAPK pathways in ADPKD cyst-lining epithelial cells. These inhibitory effects of rosiglitazone were reversed by the PPARγ specific antagonist GW9662 and PPARγ siRNA. ADPKD cyst-lining epithelial cells participate in TGF-β1 mediated fibrogenesis. Rosiglitazone could suppress TGF-β1–induced collagen type I and fibronectin expression in ADPKD cyst-lining epithelia through modulation of the Smad2 pathway. Our study may provide therapeutic basis for clinical applications of rosiglitazone in retarding the progression of ADPKD.Keywords
This publication has 51 references indexed in Scilit:
- PPAR-γ agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney diseaseAmerican Journal of Physiology-Renal Physiology, 2011
- Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networksHuman Molecular Genetics, 2009
- Polycystic Kidney DiseaseAnnual Review of Medicine, 2009
- TGF-β Mediated Epithelial-Mesenchymal Transition in Autosomal Dominant Polycystic Kidney DiseaseYonsei Medical Journal, 2009
- Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1Human Molecular Genetics, 2008
- Peroxisome Proliferator-Activated Receptor-(PPAR-) Agonists Attenuate the Profibrotic Response Induced by TGF-1 in Renal Interstitial FibroblastsMediators of Inflammation, 2007
- Plasticity of epithelial cells derived from human normal and ADPKD kidneys in primary culturesCell and tissue research, 2007
- Gene profiling of polycystic kidneysNephrology Dialysis Transplantation, 2006
- Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)? activatorsClinical and Experimental Nephrology, 2003
- Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in ratsKidney International, 2001